



Delivering Meaningful Patient Outcomes with Advanced Dendrimer Technology

19th Bioshares Biotech Summit | 7 & 8 August 2025

CEO, Cheryl Maley



Disclaimer and Forward-Looking Statements

This presentation contains forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable at this time, Starpharma can give no assurance that these expectations will prove to be correct. Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, risks associated with patent protection, future capital needs or other general risks or factors.

Our Mission

“To help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology.”



Who is Starpharma?

An innovative, biopharmaceutical company and **leader in dendrimer technology**

Starpharma uses its **dendrimer technology** to create **proprietary, patented DEP® products** by attaching therapeutic compounds to dendrimers.

DEP® dendrimers act as a versatile **scaffold** that can be **tailored** to carry a wide range of **drug** or **radioactive payloads**, **control** their **activity**, and **target specific locations** in the body, such as a tumour or a particular cell type.



Clinically validated DEP® technology

More than 350 patients treated with DEP® across multiple clinical programs.



Uniquely experienced team

20 years of deep expertise in dendrimer science. Staff of ~40 people.



Strong intellectual property position

21 active patent families with over 200 granted and pending patents.



Pipeline of products and partnerships

Portfolio includes clinical-stage assets, early-stage research, partnerships, and commercial products.


Advancing Patient Outcomes with Next-Generation Dendrimer Technology



Dendrimers are highly branched (tree-like) macromolecules with a well-defined, 3D structure.

DEP® dendrimers are constructed in concentric layers of lysine monomers called generations.

DEP® dendrimers are easily scalable, precisely manufactured, and Good Manufacturing Practice (GMP) certified.





DEP[®] Technology Solving Complex Drug Challenges

Addressing limitations of a wide range of diagnostics and therapies

Starpharma's DEP[®] technology contributes to **better patient outcomes and improved quality of life**, and **bridges the gap** between small and large molecule targeting and payload delivery modalities



The Challenges

Insufficient **tumour exposure**. necessity to use high potent actives

Clearance, half-life, off-target tissue uptake

Manufacturing, heterogeneous **conjugation**, **solubility** challenges

Efficacy

Toxicity / PK

Chemistry



The DEP[®] Solution

Improved tumour penetration / retention, **increased payload** or targeting moieties per molecule

Modifiable size, solubility, linkers and **payloads**


Scalable, reproducible, site-specific attachment



Pre-clinical Validation of DEP[®] Dendrimers


Modifying generation (size) improves tumour accumulation via EPR, leading to improved efficacy

DEP[®] allows better targeting of drugs to cancer tissue resulting in higher drug levels




MDA-MB-231 breast cancer model

Radiolabelled DEP[®] dendrimer-drug conjugate accumulates in tumour via EPR effect



DU145 prostate cancer model



DEP[®] cabazitaxel shows enhanced efficacy vs. standard cabazitaxel (S-CTX)



DEP® SN38 Phase II Study Shows Favourable Efficacy and Tolerability Data in Late-Stage Patients

Results Presented at the 2024 ASCO Annual Meeting

2024 ASCO®
ANNUAL MEETING




Data for DEP® SN38 in combination with 5-FU/LV; Full Phase II results reported in ASX Announcement dated 27 May 2024; *From published data on irinotecan in combination with 5-FU/LV, Tournigand et al., *Clin Oncol*, 2023, 41(19):3469-3477; # <https://www.medicines.org.uk/emc/product/6506>- UK SmPC April 2022

[#]From published data on ICC (investigator chemotherapy of choice) (pegylated liposomal doxorubicin, paclitaxel, or topotecan), Pujade-Lauraine E, et al., *J Clin Oncol*, 2014, 32(13):1302-1308;

Addressing the Biodistribution Challenges of Current Approaches with DEP® Radiotheranostics




Biodistribution Challenges with Other Approaches:




LHS Image from Lizak et al, 2024, SNMMI presentation – DLL3 Radio-DARP in in tumor mouse model



Starpharma's DEP® Technology Solution:




DEP® HER2 radiodiagnostic: faster clearance from blood and sustained elevated tumour:blood ratios compared to trastuzumab-⁸⁹Zr



Learnings from a Drug Delivery Platform Technology



Over **two decades** exploring the potential of the dendrimer technology has taught us:



Opportunity vs Focus


Ease vs Unmet Need

Partnership
Alignment

Need for Speed

Starpharma's DEP® Platform Technology: Versatile and Multifunctional for Delivery of Therapeutics and Diagnostics

Multiple Opportunities to Maximise Shareholder Returns





Our Strategy for Delivering Shareholder Value

Our vision is to be **globally recognised as a leader in innovative drug delivery, creating significant value for our partners** through Starpharma's proprietary dendrimer technology — **advancing patient outcomes and commercial success.**

01

Maximise DEP[®] Platform Value

Create novel assets and exemplify the benefits of the dendrimer technology in emerging therapy areas

02

Build Strategic Partnerships

Engage early, align on goals, and execute with strong collaboration for long-term value creation

03

Build Long-term Sustainability

Increase revenue, strengthen IP position, and continue fostering a high-performance culture



Key Focus Areas in The Next 12 Months



1) License Opportunity Conversion



2) Radiotheranostic Progress to the Clinic



3) New Strategic Partnerships



4) Increasing Revenue Contributing to Sustainability

Q&A





ASX : SPL
US OTC : SPHRY

Thank you.

Investor Relations

Investor.Relations@Starpharma.com

www.starpharma.com

Corporate Office

4 – 6 Southampton Crescent

Abbotsford, Victoria 3067

Australia

